[go: up one dir, main page]

PE20080269A1 - Composicion farmaceutica que contiene un anticuerpo monoclonal anti idiotipico anti-ca-125 y aluminio - Google Patents

Composicion farmaceutica que contiene un anticuerpo monoclonal anti idiotipico anti-ca-125 y aluminio

Info

Publication number
PE20080269A1
PE20080269A1 PE2007000831A PE2007000831A PE20080269A1 PE 20080269 A1 PE20080269 A1 PE 20080269A1 PE 2007000831 A PE2007000831 A PE 2007000831A PE 2007000831 A PE2007000831 A PE 2007000831A PE 20080269 A1 PE20080269 A1 PE 20080269A1
Authority
PE
Peru
Prior art keywords
aluminum
idiotipic
antibody
pharmaceutical composition
composition containing
Prior art date
Application number
PE2007000831A
Other languages
English (en)
Inventor
Jens Flemming
Karsten Groger
Reinhard Schmitz
Stefano Manzini
Original Assignee
Menarini Internat Operation Luxembourg S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Menarini Internat Operation Luxembourg S A filed Critical Menarini Internat Operation Luxembourg S A
Publication of PE20080269A1 publication Critical patent/PE20080269A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UN ANTICUERPO MONOCLONAL ANTI-IDIOTIPICO ANTI-CA125 MEN 2234 (ABAGOVOMAB) QUE COMPRENDE LA SEQ ID NO 1 Y SEQ ID NO 2 Y SE ENCUENTRA EN UNA CONCENTRACION DE 0.1 A 4 MG/ML; Y B) UN COMPUESTO DE ALUMINIO TAL COMO HIDROXIDO DE ALUMINIO O FOSFATO DE ALUMINIO COMO ADYUVANTE EN UNA CONCENTRACION DE 2.4 A 5.2 MG/ML. DICHA COMPOSICION ESTA SUSPENDIDA EN UNA SOLUCION SALINA TAMPONADA E ISOTONICA PARA ADMIISTRACION PARENTERAL Y ES UTIL EN EL TRATAMIENTO DE TUMOR OVARICO
PE2007000831A 2006-06-29 2007-06-27 Composicion farmaceutica que contiene un anticuerpo monoclonal anti idiotipico anti-ca-125 y aluminio PE20080269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000163A ITFI20060163A1 (it) 2006-06-29 2006-06-29 Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio

Publications (1)

Publication Number Publication Date
PE20080269A1 true PE20080269A1 (es) 2008-05-09

Family

ID=37439367

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000831A PE20080269A1 (es) 2006-06-29 2007-06-27 Composicion farmaceutica que contiene un anticuerpo monoclonal anti idiotipico anti-ca-125 y aluminio

Country Status (34)

Country Link
US (2) US20100040625A1 (es)
EP (2) EP2040749B1 (es)
JP (1) JP2009541448A (es)
KR (1) KR20090024240A (es)
CN (1) CN101478987A (es)
AP (1) AP2009004741A0 (es)
AR (1) AR061364A1 (es)
AT (1) ATE502649T1 (es)
AU (1) AU2007263690A1 (es)
BR (1) BRPI0713343A2 (es)
CA (1) CA2655733A1 (es)
CL (1) CL2007001888A1 (es)
CR (1) CR10589A (es)
CY (1) CY1111527T1 (es)
DE (1) DE602007013402D1 (es)
DK (1) DK2040749T3 (es)
EA (1) EA015543B1 (es)
EC (1) ECSP099089A (es)
ES (1) ES2363616T3 (es)
HR (1) HRP20110413T1 (es)
IL (1) IL196148A0 (es)
IT (1) ITFI20060163A1 (es)
MA (1) MA30691B1 (es)
MX (1) MX2008016059A (es)
NO (1) NO20090395L (es)
PE (1) PE20080269A1 (es)
PL (1) PL2040749T3 (es)
PT (1) PT2040749E (es)
RS (1) RS51683B (es)
SI (1) SI2040749T1 (es)
TN (1) TNSN08485A1 (es)
UA (1) UA95806C2 (es)
WO (1) WO2008000789A2 (es)
ZA (1) ZA200900563B (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio
AU2012250924B2 (en) 2011-05-02 2017-05-25 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration
US10799597B2 (en) 2017-04-03 2020-10-13 Immunomedics, Inc. Subcutaneous administration of antibody-drug conjugates for cancer therapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5127731B1 (es) * 1971-05-12 1976-08-14
FR2565825B1 (fr) * 1984-06-15 1990-07-13 Centre Nat Rech Scient Vaccin contre les maladies dues a des microorganismes tels que des mycoplasmes, sa preparation et membranes de microorganismes en tant que principe actif
CA2163868C (en) 1993-05-27 2008-01-08 Uwe Wagner Monoclonal anti-idiotypic anti-ca125 antibodies and pharmaceutical compositions containing them
US5718904A (en) * 1995-06-02 1998-02-17 American Home Products Corporation Adjuvants for viral vaccines
US5690942A (en) * 1995-06-02 1997-11-25 American Home Products Corporation Adjuvants for viral vaccines
GB9808485D0 (en) * 1998-04-21 1998-06-17 Univ Cambridge Tech Improvements relating to immunotherapy
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
US6585981B1 (en) * 2000-07-27 2003-07-01 Regents Of The University Of Minnesota Temperature-sensitive live vaccine for Mycoplasma hyopneumoniae
CU23007A1 (es) * 2001-04-06 2004-12-17 Ct De Inmunologia Molecular Ct De Inmunologia Mole Combinaciones inmunoterapéuticas para el tratamiencombinaciones inmunoterapéuticas para el tratamiento de tumores que sobre-expresan gangliósidos to de tumores que sobre-expresan gangliósidos
US7537767B2 (en) * 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
ITFI20060163A1 (it) * 2006-06-29 2006-09-28 Menarini Internat Operations Luxembourg Sa Composizione farmaceutica contenente un anticorpo monoclonale anti idiotipico anti-ca-125 ed alluminio

Also Published As

Publication number Publication date
PT2040749E (pt) 2011-06-30
ITFI20060163A1 (it) 2006-09-28
WO2008000789A3 (en) 2008-02-28
ES2363616T3 (es) 2011-08-10
ATE502649T1 (de) 2011-04-15
CR10589A (es) 2009-03-30
DE602007013402D1 (de) 2011-05-05
KR20090024240A (ko) 2009-03-06
US20100040625A1 (en) 2010-02-18
TNSN08485A1 (en) 2010-04-14
CN101478987A (zh) 2009-07-08
BRPI0713343A2 (pt) 2012-03-13
NO20090395L (no) 2009-01-27
JP2009541448A (ja) 2009-11-26
CL2007001888A1 (es) 2008-04-18
WO2008000789A2 (en) 2008-01-03
SI2040749T1 (sl) 2011-06-30
RS51683B (sr) 2011-10-31
CY1111527T1 (el) 2015-08-05
IL196148A0 (en) 2011-08-01
ECSP099089A (es) 2009-02-27
MA30691B1 (fr) 2009-09-01
EP2040749A2 (en) 2009-04-01
US20090104184A1 (en) 2009-04-23
AU2007263690A1 (en) 2008-01-03
MX2008016059A (es) 2009-01-15
EA015543B1 (ru) 2011-08-30
AR061364A1 (es) 2008-08-20
HK1126417A1 (en) 2009-09-04
UA95806C2 (ru) 2011-09-12
DK2040749T3 (da) 2011-06-14
EA200900085A1 (ru) 2009-06-30
AP2009004741A0 (en) 2009-02-28
EP2040749B1 (en) 2011-03-23
ZA200900563B (en) 2010-03-31
PL2040749T3 (pl) 2011-09-30
HRP20110413T1 (hr) 2011-07-31
EP2228073A1 (en) 2010-09-15
CA2655733A1 (en) 2008-01-03

Similar Documents

Publication Publication Date Title
ES2569409T3 (es) Composiciones de anticuerpo anti-CTLA-4
PE20120205A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y citarabina
CL2019002056A1 (es) Composición para el tratamiento de una infección por staphylococcus aureus que contiene solo un anticuerpo o un polipéptido anti leucocidina lukd, lukd aislado o un polipétido del mismo, o una combinación de ambos y portador farmaceuticamente aceptable.(divisional solicitud 201303650)
PE20220218A1 (es) Conjugados de anticuerpo-farmaco inhibidores de mcl-1 y sus metodos de uso
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
CO6230999A2 (es) Anticuerpo anti-esclerostina
PE20080269A1 (es) Composicion farmaceutica que contiene un anticuerpo monoclonal anti idiotipico anti-ca-125 y aluminio
CL2013003570A1 (es) Anticuerpo que se une al ligando-1 de glicoproteina p-selectina (psgl-1); composicion farmaceutica que comprende el anticuerpo anti-psgl-1; kit farmaceutico; dispositivo para inyeccion; y uso del anticuerpo anti psgl-1 o de la composicion que lo contine para preparar un medicamento para tratar un desorden inflamatorio.
ECSP11011157A (es) Inhibidores de proteína cinasa
AR086074A1 (es) Composiciones y metodo para tratar enfermedades autoinmunes
MX2019010282A (es) Formulacion de anticuerpos monoclonales.
UY33407A (es) Anticuerpos específicos del factor gdf8 humano
CO6180466A2 (es) Composiciones y metodos para diagnosticar y tratar cancer
ES2689746T3 (es) Anticuerpos monoclonales contra la claudina-18 para el tratamiento de cáncer
CR20140555A (es) Peptidomimeticos de smac útiles como inhibidores de proteínas de apoptosis (iap)
PE20091352A1 (es) Composicion que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes acidas
AR054427A1 (es) Tratamiento de trastornos oseos
NZ610294A (en) Human antibodies to human tnf-like ligand 1a (tl1a)
PE20140247A1 (es) Anticuerpos anti-cd38
CL2016003014A1 (es) Anticuerpos monoclonales contra el inhibidor de la vía del factor tisular (tfpi) (divisional sol. n°230-11).
CL2008003782A1 (es) Anticuerpo bivalente bioespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un primer antigeno donde el dominio ch3 se reemplaza por ch1, y la cadena ligera y pesada de un anticuerpo que se une a un segundo antigeno, en el que el dominio ch3 esta reemplazado por cl; metodo de preparacion; y composicion.
PE20080035A1 (es) Anticuerpos monoclonales humanos para la quinasa-1 tipo receptor de activina
AR083239A1 (es) Compuestos de tratamiento de pozo para uso en fluidos de tratamiento de pozo
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos

Legal Events

Date Code Title Description
FC Refusal